EMA Authorised: Pramipexole Teva (pramipexole dihydrochloride monohydrate) — Teva Pharma B.V.

View source ↗

Summary

The EMA authorised Pramipexole Teva (pramipexole dihydrochloride monohydrate) for use in Parkinson disease, with Teva Pharma B.V. as the marketing authorization…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole Teva (pramipexole dihydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Teva Pharma B.V.. Decision date: 29/08/2024